Turn TherapeuticsTTRX
Recorded

Turn Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration16 minParticipants1

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Brad BurnamFounder and CEO

Appreciate the attendance. Appreciate everybody joining. Sorry about the delay, and I know that there have been a number of travel disruptions this week, so I appreciate Jefferies giving me the opportunity to present virtually. My name is Brad Burnam, founder and CEO of Turn Therapeutics. I am also the creator of the technology that we will be discussing today, so I know it quite intimately. Today, we are going to be discussing not just the company, but the programs that we are working on as well. The origin story of Turn is a bit unusual, but it is something that encompassed a large period of my life. I actually immediately spent about 10 years in sales, in medical device sales after graduate school.

Brad BurnamFounder and CEO

I worked in initially neuromodulation, then I went into the pacemaker defibrillator side of things and spent a lot of time in the hospitals, a lot of interaction with patients, a lot of time in the operating room. It also gave me a really strong familiarity with what it is like to actually be a medical rep in the field, which gives me a unique commercial perspective when I am developing products and looking at their pros and cons per se. Because of interacting with patients, you also are susceptible to organisms, and contagious diseases, and such things. I actually picked up a hospital-acquired infection in December of 2009 through work, which led me to have about three years of chronic wounds.

Brad BurnamFounder and CEO

I spent six months at a time, six days a week in advanced wound care clinics, getting chronically infected wounds packed, and it gave me a very strong familiarity with what was being used in the wound care space, which is where Turn began. It also gave me a bit of a frustration with the products that were in use in that space, products like Neosporin and honey and silver-based products that I felt were not necessarily up to the level of technology we were seeing in the therapeutic side. So, it became a goal for me to create a better wound care product, not just for everybody to use, but initially for me to use. I wanted to get my wounds to close. I found an API called polyhexanide in Europe that had been used extensively in European countries as a wound flush, as an antimicrobial, as an anti-inflammatory.

Brad BurnamFounder and CEO

As a liquid API, it was not necessarily suitable for a viscous ointment, which is what I was hoping to make for a wound care product in the U.S. But I was able to formulate it inside of an oil carrier using a process that we call PermaFusion now, which is permanently suspending a polar water-soluble ingredient inside of an oil carrier without an emulsifier. Very unique properties. It allows us to use less of the API while still actually having the same bioavailability as if it were more. Using that process, I created GX-03, which is sort of our flagship formula still to this day. It has an interesting novel MOA. It has IL-36 reduction, IL-31 reduction. We will talk about that later. It also has effects on microbes such as bacteria, fungus, and yeast.

Brad BurnamFounder and CEO

I was able to actually get FDA clearance for this formula, initially in the beginning, just sort of on my own with some seed funding at the end of 2016. Then we got two more actually in the wound care space in 2017 and 2019. Over the course of this product being out there, initially as a wound care product, we saw use in over 200,000 people, and we saw a lot of other use profiles that doctors were using it for. Most consistently, we saw it in eczema and in tinea fungus. These were not things that I was initially thinking about in the wound care space, but therapeutic use cases that were becoming more and more prominent that we were seeing reports and publications about. I sought some help. You will see we have a pretty amazing team of board members, advisors, and team members, because in this therapeutic side, I needed guidance.

Brad BurnamFounder and CEO

They told me to essentially bifurcate the company, treat the wound care side as a consistent, potentially passive revenue generator using some of the assets that obtained clearance, then focus on the therapeutic development of the main formula, GX-03. I wanted to really understand why it was helping people in eczema, why these reports were coming in that the itching was going away, that the skin was healing so well. I understood on the wound care side that it could actually help heal the skin, but why were they reporting that they were having reduced symptoms in terms of such things as itching and quality of life?

Brad BurnamFounder and CEO

I had a working theory that we were affecting the initial cytokine release in the inflammatory skin cascade, or IL-36. IL-36 is actually the only in vivo measurement for whether or not the epithelium is under duress. If you cut your skin, if it is cold and it cracks, if there is an inflammatory insult to the skin, if there is a pathogenic insult, the skin first releases IL-36, which leads to the downstream effects we know of, such as TH2, IL-31. You see your 4s and your 13s under the TH2 area. People are very familiar with those.

Brad BurnamFounder and CEO

I had a theory that we were actually blunting that initial response and therefore reducing the downstream effects of the additional cytokines, and we proved this over two publications that we put out this past year, that we inhibited IL-36 and a very large amount of IL-31 as well, which is the quality of life, neuroeffective cytokine that affects itching. From this point, we knew that we had a strong safety profile, given its history in the wound care space, an interesting mechanism of action theory that we were able to put out in those publications. We wanted to try this drug in humans, specifically for atopic dermatitis. Now, going into a phase IIa, we needed to enable it obviously with an endpoint, but we really wanted to treat this first stage. You can call it stage 1, stage 2.

Brad BurnamFounder and CEO

I prefer to think of it as a phase II-A, a phase II-B. It's up to people how they want to refer to it. But we took this first 50 patients. We used a very wide inclusion criteria. You just needed to have an IGA of at least three or an EASI of at least seven to be included in the trial. And we wanted to look at it at the end of the 50 patients using an IDMC and then optimize stage 2 based upon what we saw. And we really looked at these four main efficacy endpoints as targets. Week 4 IGA is something people are very familiar with. A lot of products have this as a registrational endpoint, like Pfizer's drug, for example. EASI targets are not as common in topicals. We typically see them focusing solely on IGA. This tends to be more biologics.

Brad BurnamFounder and CEO

But we saw some interesting separation in the ITT group. When you're building a trial out for the optimized stages, you want to look toward enrichment targets. What's an enrichment target? It's how you can sort of focus on one endpoint or another, focus on one criteria or another to actually show the drug signal the best. Most systemic drugs, and frankly, a lot of even topical drugs, really look at patients with a higher EASI. We noticed that we had effectiveness across the whole EASI spectrum, 1.1 and up. And we didn't necessarily want to limit ourselves to that. We wanted to keep our patients in the IGA of three or four, the moderate to severe lesion, but we wanted to make sure that we had the entire EASI spectrum covered. So, we found another interesting potentially candidate biomarker in pruritus.

Brad BurnamFounder and CEO

So pruritus is obviously the itch score, PP-NRS. If you see that as we went up in the self-reported itch, see PP-NRS of five, which is just that midpoint of 0 to 10, 40 of the patients had at least that. We saw actually statistically significant separation in the week 4 IGA. It's 40 people, 80% of the trial. As we went up to six, 35 patients, we saw an even greater separation. As we hit the seven mark, we saw sort of a broader separation across multiple endpoints, including 46.2% versus 8.3% at EASI-100 week eight, which is an incredible potential endpoint to be pursuing.

Brad BurnamFounder and CEO

And we decided that for stage 2 of the trial, even though we plan on including five and six in our phase III program, for the sake of efficiency, we're going to use PP-NRS as an enrichment target while keeping the full EASI spectrum. So, the current stage 2 or phase II-B of our adaptive trial looks a bit like this, which I'll put into English, of course. We have all 3 EASI buckets, stratum, the fancy term is, of course, but it's the different sides of the spectrum. We've got our lower EASI quartile, 1.1 to 7. You can think of that as the patients with maybe just severe hand eczema or severe face eczema. Then our moderate coverage, 7.1 to 15.9. And then, of course, our EASI of greater than or equal to 16, which is where we see our systemic drugs usually targeted.

Brad BurnamFounder and CEO

We're enriching for PP-NRS of seven, as we mentioned. Anybody with an EASI of 1.1 or up is eligible, and it's a BID topical eight-week trial. If we took this criteria and we overlaid it back on the first 50 people, you see an EASI curve that is very encouraging. You see a pretty large separation at the week four mark. The fast and safe target is what we're really targeting. Continued separation into week eight. Of course, you're going to get some compression considering our placebo is an ointment. If you look at this chart, this table of what our phase IIa would have looked like with the exact design of our phase IIb, we see a week 4 IGA success with a 0.01 p-value. It was a wonderful surprise that we got this incredible level of separation once we put this back in there.

Brad BurnamFounder and CEO

Looking down the list, week 4 EASI 75. We have to remember that EASI 75, EASI 90, EASI 100 are not typical topical targets. Typically, we're really just looking at IGA. It's pretty amazing to see some separation into where we're used to seeing the systemic injectables. Again, the drum that I beat all the time is safe, fast, and safe. That is the commercial premise that we're pursuing. We only had one patient with a mild warming sensation on the drug side. Another on the placebo side reported a common cold. That was across all 50 patients for eight weeks at at least two time-of-day application. As we know, this is a very large market with varied treatment options.

Brad BurnamFounder and CEO

Usually, the people in the less than 14 to 16 EASI are left with topicals, things like steroids and Vtama and OPZELURA, because their insurance doesn't qualify them for the systemics because their EASI coverage of their body is not as high. We think that those people should have options other than those, and that's a very large opportunity for us in this space and also for the patients. We don't necessarily think that we would replace biologics. I think it would be kind of loony for a CEO to say that. There is no reason for a product that can't help bridge to those biologics that is non-systemic, doesn't have a large side effect profile, and can get those people feeling better while they're bridging onto their biologics. So, another indication that we saw a great deal of use in is onychomycosis, or toenail fungus.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day